Expect continued downward pressure from the overhang of potential conversion shares, as the lender can convert at a deep discount to market. Monitor for the registration statement filing (due by July 1, 2026) which will enable resale of conversion shares, likely accelerating selling. The small cash infusion ($663k new) is insufficient to fund operations for long, raising the risk of further dilutive financings.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 29 $0.0110entry
- T+1 · 5mo ago 0.00%α −0.78% · $0.0110
- T+5 · 4mo ago −7.27%α −8.66% · $0.0102
- T+20 · 4mo ago −11.82%α −11.56% · $0.009700
- T+60 · 8w ago −9.09%α −12.14% · $0.0100
Price Chart
How similar events traded
Executive Summary
CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions, providing up to $1,413,600 in net proceeds (with 25% OID) of which $663,600 was newly funded. The note carries a 10% interest rate, matures May 2027, and is convertible into common stock at a deeply discounted variable price (floor $0.05 or 80% of the 5 lowest intraday prices over 20 days). The terms are highly dilutive and signal financial distress, as the company is raising minimal cash on predatory terms from a single lender.
Key Financial Metrics
Key Facts
- Maximum loan amount of $1,413,600 net proceeds ($1,767,000 principal with 25% OID); $750,000 previously funded, $663,600 new funding on June 23, 2026.
- Conversion price is the lesser of $0.05 (floor) or 80% of the average of the 5 lowest intraday trading prices over the prior 20 days.
- 10% annual interest, maturity May 28, 2027.
- Company must file a resale registration statement for conversion shares by July 1, 2026.
- Lender is limited to 4.99% beneficial ownership cap.
Financial Impact
Up to $1,413,600 in gross proceeds, but with 25% OID the effective cash received is $1,413,600 against a $1,767,000 principal. Conversion at deep discount will cause substantial dilution; exact share count depends on stock price at conversion.
Risk Factors
- Massive dilution from conversion of the note at deeply discounted prices.
- Limited cash runway; additional dilutive financing likely needed.
- Potential default if stock price remains low and conversion terms become even more unfavorable to existing shareholders.
- Registration of conversion shares could lead to immediate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-072602 |
| Document: ea0296022-8k_cero.htm | 0001213900-26-072602 |
| Document: 0001213900-26-072602-index-headers.html | 0001213900-26-072602 |
| Document: 0001213900-26-072602-index.html | 0001213900-26-072602 |
| Document: 0001213900-26-072602.txt | 0001213900-26-072602 |
Track record
5 reports on CERO
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +65.71% at T+60 after the Mar 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Oct 7, 20265w ago 8-K Bearish 6/10 Entry $0.0951 Now $0.005000 +94.74% No price data
- Aug 31, 202611w ago 8-K Bearish 7/10 Entry $0.0120 to $0.0105 Now $0.005000 +58.33% ▲ +12.50% +13.68% vs SPY
- Jul 13, 202618w ago 25-NSE Bearish 7/10 Entry $0.0150 to $0.0100 Now $0.005000 +66.67% ▲ +33.33% +36.52% vs SPY
- Jun 26, 202620w ago 8-K Bearish 6/10 Viewing Entry $0.0110 to $0.009700 Now $0.005000 +54.55% ▲ +11.82% +11.56% vs SPY
- Mar 11, 202635w ago 8-K Bearish 7/10 Entry $0.0350 to $0.0340 Now $0.005000 +85.71% ▲ +2.86% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers